ITI Pharma and Healthcare Fund
Pharma and Healthcare · Direct plan · Growth
₹20.70
+₹0.13 (+0.63%) today
NAV on 20 Nov 2026 · Near its 52-week high
Returns
Up to a year
| Period | This fund | NIFTY Healthcare | Rank |
|---|---|---|---|
| 1 month | +11.35% | +12.34% | 12/19 |
| 3 months | +4.42% | +6.15% | 8/18 |
| 6 months | +12.33% | +10.59% | 12/18 |
| This year | +21.31% | +19.97% | 12/18 |
| 1 year | +18.01% | +18.04% | 13/17 |
Longer term
| This fund | NIFTY Healthcare | NIFTY Healthcare | Category | ||||
|---|---|---|---|---|---|---|---|
| Total | A year | Total | A year | A year | Rank | ||
| 2 years | +18.14% | +8.7% | +13.0% | – | |||
| 3 years | +72.63% | +20.0% | +20.9% | 9/12 | |||
| 5 years | +107.9% | +15.8% | +15.6% | 8/10 | |||
| 7 years | – | – | +21.2% | – | |||
| 10 years | – | – | +12.3% | – | |||
| Since inception | +107.0% | +15.6% | +15.6% | – | |||
₹1 lakh invested 5 years ago is ₹2.08 lakh today.
From the plan's own NAV, to 20 Nov 2026. Rank 1 is best. Past returns are no guide to the future.
RiskWorst fall -17.7% · volatility 16.5% a year
Volatility, 3 years
16.5%
NIFTY Healthcare 16.4%
Worst fall
-17.7%
Jun 2022, back by Jun 2023
Worst calendar year
-8.2%
2025
Up months
72%
last 3 years
Against other pharma and healthcare funds, last 3 years (worst fall: 5 years)
Volatility
= 16.5%
In line with peers · average 16.0%
11 of 13
Worst fall
= -17.7%
In line with peers · average -18.2%
4 of 10
Sharpe ratio
! 0.84
Less return for the risk · average 0.99
9 of 12
Yearly cost
✓ 0.86%
Cheaper than peers · average 1.10%
3 of 18
More measures ›Fewer measures ‹
Sharpe ratio, 3 years
0.84
Return above the CRISIL Overnight Index per unit of volatility
Sortino ratio, 3 years
1.48
The same, counting only falls
Alpha vs NIFTY Healthcare
-0.41%
Yearly return beyond what its beta explains
Beta vs NIFTY Healthcare
0.96
Moves this much when the index moves 1%
Share of the index's rises
93%
In months the index rose
Share of the index's falls
89%
In months the index fell; lower is better
Over the last 3 years, from the fund's NAVs against the NIFTY Healthcare.
Where it ranksAgainst 19 pharma and healthcare funds
Category rank, year by year
In the top half of pharma and healthcare funds in 2 of 5 calendar years.
Top quarter in 0, bottom quarter in 2.
12/18
Rank in 2026 YTD
'172017
N/A
'182018
N/A
'192019
N/A
'202020
N/A
'212021
N/A
'222022
Q2
4/10
'232023
Q4
9/10
'242024
Q2
4/13
'252025
Q4
16/16
'262026YTD
Q3
12/18
Each year ranks the pharma and healthcare funds by that year's return from their own Direct Growth NAV; Q1 is the top quarter. 2026 is year to date. The peer group is today's funds, so funds that closed or merged in earlier years are not counted. Past performance does not indicate future returns.
Where it ranks
among 19 pharma and healthcare funds, Direct plans1 year
13 of 17
Bottom quarter
3 years
9 of 12
Third quarter
5 years
8 of 10
Bottom quarter
Lowest cost
3 of 18
Top quarter
| Best over 3 years | 3 years | A year | Cost | Size |
|---|---|---|---|---|
| 1HDFC Pharma and Healthcare Fund | +123.0% | +30.6% | 1.04% | ₹3,666 Cr |
| 2SBI Healthcare Opportunities Fund | +94.4% | +24.8% | 1.00% | ₹6,067 Cr |
| 3Mirae Asset Healthcare Fund | +90.9% | +24.0% | 0.61% | ₹3,562 Cr |
| 4UTI Healthcare Fund | +87.3% | +23.3% | 1.34% | ₹1,433 Cr |
| 5LIC MF Healthcare Fund | +80.9% | +21.9% | 1.38% | ₹96.54 Cr |
| 9ITI Pharma and Healthcare Fund this fund | +72.6% | +20.0% | 0.86% | ₹267 Cr |
Every fund in the category computed from its own NAV the same way, to 20 Nov 2026. All Pharma and Healthcare funds ›
What stands out
What it holds
38 holdings · as of Aug 2026
- 1Sun Pharmaceutical Industries Ltd12.58%
- 2Divi'S Laboratories Ltd9.23%
- 3Apollo Hospitals Enterprises Ltd5.72%
- 4Max Healthcare Institute Ltd4.84%
- 5Torrent Pharmaceuticals Ltd4.75%
- 6Dr. Reddys Laboratories Ltd4.31%
- 7Cipla Ltd4.22%
- 8Laurus Labs Ltd4.02%
- 9Aurobindo Pharma Ltd3.97%
- 10Mankind Pharma Ltd3.31%
SIP returns of pharma and healthcare funds · All pharma and healthcare funds · Fund screener
About ITI Pharma and Healthcare Fund Direct Plan Growth Option
ITI Pharma and Healthcare Fund Direct Plan Growth Option is a Sector Specific - Pharma equity fund from ITI Asset Management Limited, launched on 8 Nov 2021. Its benchmark is the NIFTY Healthcare Index. The expense ratio is 0.86% a year. It manages ₹267 crore. The NAV was ₹20.70 on 20 Nov 2026.
Questions about ITI Pharma and Healthcare Fund
What is the NAV of ITI Pharma and Healthcare Fund Direct Growth?
The NAV of ITI Pharma and Healthcare Fund Direct Growth was ₹20.70 on 20 Nov 2026. Mutual fund NAVs are published once a day, after markets close.
What are the returns of ITI Pharma and Healthcare Fund Direct Growth?
ITI Pharma and Healthcare Fund Direct Growth returned 18.0% over 1 year, 20.0% a year over 3 years and 15.8% a year over 5 years, to 20 Nov 2026, worked out from its own daily NAV. It returned more than the NIFTY Healthcare Index in 4 of 6 calendar years since 2021.
What is the expense ratio of ITI Pharma and Healthcare Fund Direct Growth?
0.86% a year. It is taken from the fund's assets every day, so the NAV and every return shown are already after this cost.
Can NRIs in the UAE invest in ITI Pharma and Healthcare Fund?
NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. ITI Mutual Fund accepts investors living in the US or Canada only on conditions, per its own documents checked on 15 Nov 2026. Rules change, so confirm with the fund house.
How are ITI Pharma and Healthcare Fund gains taxed for NRIs?
India taxes gains on equity funds at 20% on units held 12 months or less, and at 12.5% on gains above ₹1.25 lakh a year on units held longer, plus cess and any surcharge. For NRIs the tax is deducted when units are redeemed. The UAE has no personal income tax, and the India UAE tax treaty may apply, so confirm your position with a tax adviser.
Rolling returns shows every period, not just the latest.
Compare every pharma and healthcare fund on returns, volatility, worst fall and cost.

















